CompletedPhase 2NCT01778556
Short-term Effects of Leptin in People With Lipodystrophy
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Rebecca J Brown, M.D.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Intervention
- Metreleptin(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 14-70 years · All sexes
- Timeline
- 2013 – 2018
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01778556 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07091734Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024University of Michigan
- RECRUITINGNCT02325674MEASuRE: Metreleptin Effectiveness And Safety RegistryAmryt Pharma
See all trials for Lipodystrophy due to peptidic growth factors deficiency →